ELSEVIER

Author Index
Volumes 37 and 38

A
Addison RS, 38:19
Agarwal N, 37:229
Agrawal DK, 37:215
Akira K, 37:237
Albrecht RM, 37:15
Allen RT, 37:215
Anderson KM, 38:133
Anderson WP, 38:33
Aquirre L, 38:93
Arboix M, 37:191
Ardid D, 38:109
Atassi G, 37:105
Attolini L, 38:195

B
Baker GB, 37:129, 38:27
Barr RL, 38:11
Barrett TD, 37:27
Benner E, 37:229
Bennett G, 37:167
Bennett GW, 37:143
Berg J, 37:179
Bernard CE, 38:41
Bishop MR, 37:229
Bjorling DE, 37:15
Bodenteich A, 37:179
Bonina F, 37:135
Borges DR, 37:23
Bourin M, 37:129
Brand IA, 38:181
Britt D, 37:1
Broadley KJ, 37:161
Bruguerolle B, 38:195

C
Camarasa J, 38:93
Camins A, 38:93
Carretero A, 37:191
Castelli F, 37:135
Chan C, 37:1
Chan R, 38:157
Chapuy E, 38:109
Cheung PH, 38:133
Christoph T, 37:179
Ciocci G, 38:169
Colbourne PD, 38:27
Coutts RT, 37:129, 38:27
Cox EH, 38:99
Cristòfol C, 37:191

D
Dahlby R, 38:41
Danahay H, 37:161
Danhof M, 38:81, 38:99
D'Atri G, 37:91
De Jong PE, 38:47
De Kanter R, 38:59
De Zeeuw D, 38:47
Di Pierro F, 37:91
Dobson GL, 37:47

E
Eschalier A, 38:109
Escubedo E, 38:93
Evans RG, 38:33
Ezrin A, 37:1

F
Feuerstein TJ, 37:187
Fitzgerald SM, 38:33

G
Gabriel C, 38:93
Gantenbein M, 38:195
Graver M, 38:151
Groen K, 38:59
Groothuis GMM, 38:59
Guenthner TM, 38:163

Journal of Pharmacological and Toxicological Methods 38, 217–219 (1998)

© 1998 Elsevier Science Inc. All rights reserved.

655 Avenue of the Americas, New York, NY 10010

1056-8719/98/$19.00
PII S1056-8719(98)00009-4

JPM Vol. 38. No. 4
December 1997:217–219

H
Haas M, 38:47
Hall DWR, 38:53
Han SB, 37:83
Harada T, 38:201
Hicks PB, 38:211
Hidalgo IJ, 37:47
Ho Y-F, 38:163
Hoener B.-A., 38:41
Hof IH, 38:59
Hong DH, 37:83
Hope W, 37:75
Hottendorf R, 37:1
Howbrook D, 38:189
Hunter WJ III, 37:215
Hutchaleelaha A, 37:9

I
Inokuma M, 38:201
Irvine RJ, 38:157
Iversen P, 37:229

J
Joseph G, 38:173
Joshi SS, 37:229
Jourdan D, 38:109

K
Kelly MD, 38:133
Kendall DA, 37:143
Kim HM, 37:83
Kiss R, 37:105
Klaus W, 38:173
Kleineke JW, 38:181
Kluppel ACA, 38:47
Komocsar WJ, 37:37
Koster HJ, 38:59
Kouyoumdjian M, 37:23
Kovanecz I, 37:143

L
Landolfi C, 169
Lautt WW, 38:141
Le Bars D, 38:109
Leeman WR, 38:59
Lefebvre RA, 37:97
Leff P, 37:167
Lehman-McKeeman LD, 37:67
Leoni F, 37:91
Li J, 37:47
Li WM, 38:1
Lopaschuk GD, 38:11
Lopez H, 37:1

M
MacLeod BA, 37:27
Malpas SC, 38:33
Manesse M, 37:191
Marchetti M, 38:169
Marcucci F, 37:91
Marietta MP, 37:47
Marsden CA, 37:143
Matsunaga T, 38:201
Mattiazzi A, 37:205
Mayersohn M, 37:9
McCabe PJ, 37:161
McNeill JH, 38:1
Meijer DKF, 38:47
Metz HN, 38:151
Milanese C, 38:169
Mitsui T, 38:201
Moolenaar F, 38:47
Morris DL, 37:37, 37:55
Mortimer RH, 38:19
Mozaffari MS, 37:197
Murano H, 38:201
Myers CR, 37:61
Myers JM, 37:61

N
Nagaoka MR, 37:23
Navarro M, 37:191
Nials AT, 37:161
Nikolic SD, 38:151

O
Oh GT, 37:83
Olinga P, 38:59
Oshiro Y, 37:55

P
Palazzo RS, 38:151
Pallàs M, 38:93
Papp JGy, 37:149
Park BK, 38:71
Pasteels J-L, 37:105
Pauwels O, 37:105
Pelissier AL, 38:195
Pérez-Aparicio FJ, 37:191
Pierce TL, 37:75
Pinelli A, 38:117

Porgilsson B, 37:61
Purdon MP, 37:67

R
Rao PS, 38:151
Rao SK, 38:151
Rasiah RL, 38:19
Reinoso RF, 38:87
Rhodes GR, 37:47
Richter TJ, 38:211
Riley RJ, 38:189
Roberts MS, 38:19
Roßner R, 37:187
Romeo G, 37:135
Rotzinger S, 37:129
Rowland M, 38:87
Ruberte J, 37:191
Russell CM, 37:197
Rutten AAJJL, 38:59

S
Saban R, 37:15
Saija A, 37:135
Salem A, 37:75
Sanjar S, 37:161
Sautet J, 37:191
Scaramellini C, 37:167
Schaffer SW, 37:197
Schumacher M, 37:187
Shibutani Y, 38:201
Shinohara Y, 37:237
Shweta A, 38:33
Smits GJM, 37:97
Stevenson KM, 38:33
Straßberger F, 38:173
Sukbuntherng J, 37:9
Sureda FX, 38:93
Szekeres L, 37:149

T
Taira T, 37:237
Telfer BA, 38:87
Tengowski MW, 37:15
Thongsgaard W, 37:143
Thorén P, 37:117
Timmerman H, 38:53
Todd KG, 37:129
Tomaino A, 37:135
Tomoda F, 38:33
Trivulzio S, 38:117
Trombetta D, 37:135
Trompler RA, 38:211
Tukker (H)EJ, 38:99

U
Uccella N, 37:135
Uhlig S, 37:119

V
Van Den Berg TP, 38:53
Van Den Hoven WE, 38:53
Van Der Goot H, 38:53
Van Der Graaf PH, 38:81
Van Hemert JGN, 38:99
Van Twillert K, 38:59
Von Bethmann AN, 37:119

W
Wadenberg M-L, 38:211
Walker MJA, 37:27
Wang HH, 38:141
Warren BK, 37:197
White J, 38:157
Widerna M, 37:179
Williams P, 37:1
Wilson DW, 38:151
Wong JKL, 38:71

Y
Yeung JHK, 38:71
Yoo BS, 37:83
Young KA, 38:211

Z
Zavodny RA, 38:211
Zhang W, 37:117

ELSEVIER

Subject Index
Volumes 37 and 38

A

Accelerated infusion, effects, 37:47
Acetazolamide, carbonic anhydrase isoforms, 38:169
Acquisition, computer-controlled conditioned avoidance response, 38:211
Acyl migration, benzoic acid, 37:237
Acylglucuronide, benzoic acid, 37:237
Adenosine, epicardial coronary arteries, 38:173
α_1-Adrenoceptors, reliability, 38:81
Agonist affinity, reliability, 38:81
Agonist interactions, curve shape, 37:167
Albendazole-sulphoxide, distribution study, 37:191
Alfentanil, pharmacokinetic-pharmacodynamic modeling, 38:99
Ambulatory electrocardiography, QT interval corrected for heart rate, 38:201
Anaphylactic shock, delayed-type and immediate-type hypersensitivity reactions, 37:91
Angiometry, video, 38:173
Angiotensin II, positive inotropic effect, 37:205
Animal model, accelerated infusion, 37:47
Annexin V, apoptosis analysis, 37:215
Anti-anaphylactic drugs, delayed-type and immediate-type hypersensitivity reactions, 37:91
Anti-peptide antibodies, flavin-containing monooxygenase (FMO3), 37:61
Antibodies, Glut4 quantitation, 38:1
Antibody production, *hu*-PBL-*scid* mouse model, 37:83
Antidepressants, fluvoxamine, 37:129
Antigen, localization, 37:15
Antiinflammatory drugs, delayed-type and immediate-type hypersensitivity reactions, 37:91
Antiischemic effect, adrenoceptor agonists, 37:149
Antineoplastic agents, mechanism of action, 37:105
Antipsychotics, computer-controlled conditioned avoidance response, 38:211
Antisense oligonucleotides, hematologic malignancies, 37:229
Antiwithdrawal drug, clonidine, 38:117
Apoptosis, morphological and biochemical characterization, 37:215
Area under the curve, placental perfusion, 38:19
Arrhythmias, myocardial ischemia model, 37:27
Artifact, ear edema, 38:53
ATP production rates, energy metabolism, 38:11
Automated equipment, conditioned avoidance response, 38:211

B

Beagle dogs, QT interval corrected for heart rate, 38:201
Bisico S4i, peripheral nerve embedding, 37:117
Bladder, antigen localization, 37:15
Blood, lymphocytes, 37:37
Blood sampling device, locomotor activity measurement, 37:9
Body temperature, tobacco smoke effects, 38:195
Bronchoalveolar lavage fluid, interleukin-5 (IL-5), 37:161
Buprenorphine high-performance liquid chromatography (HPLC) analysis, 37:75

C

^{13}C-labeling, benzoic acid 1-*O*-acylglucuronide, 37:237
Calcium, angiotensin II, 37:205
Calibration, renal blood flow, 38:33
3′,5′-cAMP, effects on intracellular zinc^{2+}, 38:181
Cancer, hematologic, antisense oligonucleotides, 37:229
Captopril, effects, 38:157
Carbonic anhydrase isoforms, development and pharmacologic characterization, 38:169
Cardiac workload, adrenoceptor agonists, 37:149
Cell number, hepatocyte primary culture bioassay, 38:151
Chemotherapy, hematologic malignancies, 37:229
Chicken-embryo-toxicity, albendazole-sulphoxide, 37:191
Cocaine, pharmacokinetic/pharmacodynamic modeling, 37:9
Conditioned avoidance response, computer-controlled, 38:211

Journal of Pharmacological and Toxicological Methods 38, 221–225 (1998)

© 1998 Elsevier Science Inc. All rights reserved.

655 Avenue of the Americas, New York, NY 10010

1056-8719/98/$19.00
PII S1056-8719(98)00010-0

JPM Vol. 38. No. 4
December 1997:221–225

Confidence intervals, percentage effect, 37:187
Controlled drug input, accelerated infusion, 37:47
Coronary artery bypass graft, redox potential, 38:151
Curve shape, agonist interactions, 37:167
Cytochalasin B binding, Glut4 quantitation, 38:1
Cytochrome P-450, high-performance liquid chromatography (HPLC), 37:67

D

Daily rhythms, tobacco smoke effects, 38:195
Delayed-type and immediate-type hypersensitivity reactions, 37:91
Depolarization-evoked [^{3}H]-acetylcholine release, inhibition, 37:187
Diabetes, noninsulin-dependent, 37:197
Dichlorofluorescin, nitric oxide, 38:93
Differential scanning calorimetry, unilamellar liposomes peroxidation, 37:135
Dissociated cerebellar granule cells, nitric oxide, 38:93
Diuresis, renal function in noninsulin-dependent diabetic (NIDD) rat, 37:197
DNA fragmentation, apoptosis analysis, 37:215
Dogs
  QT interval corrected for heart rate, 38:201
  renal blood flow, 38:33
Dopamine release, measurement, 37:143
Dorzolamide, carbonic anhydrase isoforms, 38:169
Dose-additivity, agonist interactions, 37:167
Dose ramping, accelerated infusion, 37:47
Drug metabolism, incubation system, 38:59

E

Edema, permeability, 37:119
Efficacy, agonist affinity, 38:81
Egg compartments, albendazole-sulphoxide distribution, 37:191
Egg distribution, albendazole-sulphoxide, 37:191
Electrocardiography (EKG), ambulatory, 38:201
Electrochemical detection, buprenorphine high-performance liquid chromatography (HPLC) analysis, 37:75
Electroencephalogram (EEG), pharmacokinetic-pharmacodynamic modeling of alfentanil, 38:99
Electron-capture detection, metoprolol, 38:27
Electron capture gas chromatography, fluvoxamine quantification, 37:129
Elimination, accelerated infusion, 37:47
Endocytosis, vena cava perfusion in situ, 37:23
Endothelial cells, vena cava perfusion in situ, 37:23
Energy metabolism, cardiac, 38:11
Enzyme induction, 6β-hydroxycortisol, 38:71
Enzyme-linked immunosorbent assay (ELISA), 6β-hydroxycortisol, 38:71
Eosinophilia, interleukin-5 (IL-5), 37:161
Epicardial coronary arteries, video angiometry, 38:173
[*N*-Methyl-^{14}C]-Erythromycin, human hepatic CYP enzyme (CYP3A4) analysis, 38:189
Exofacial labels, Glut4 quantitation, 38:1
Experimental model, opioid withdrawal syndrome, 38:117
Extraction ratio, accelerated infusion, 37:47

F

Fatty acid oxidation, measurement, 38:11
Fieller's Theorem, confidence intervals, 37:187
Flavin-containing monooxygenase (FMO3), anti-peptide antibodies, 37:61
Flow cytometry, nitric oxide, 38:93
Fluvoxamine, electron capture gas chromatography, 37:129
FMO3. See Flavin-containing monooxygenase (FMO3)

G

Gas chromatography, metoprolol, 38:27
Gastric fundus, nitric oxide measurement, 37:93
Gene expression, quantitative competitive polymerase chain reaction (PCR), 38:133
Glut4 quantitation methods, 38:1
Guinea pigs, ovalbumin-challenged, 37:161

H

Heart rate, tobacco smoke effects, 38:195
Hematologic malignancies, antisense oligonucleotides, 37:229
Hepatectomy, partial, 38:141
Hepatocytes, measurement of intracellular zinc^{2+}, 38:181
High-performance liquid chromatography (HPLC), hydroxytestosterone metabolites, 37:67
HPLC. See High-performance liquid chromatography (HPLC)
Human erythroleukemic cell line HEL, nonsteroidal anti-inflammatory drugs (NSAIDs), 37:179
Human hepatic CYP enzyme (CYP3A4) analysis, [*N*-methyl-^{14}C]-erythromycin, 38:189
Human liver microsomes, human hepatic CYP enzyme (CYP3A4) analysis with [*N*-methyl-^{14}C]-erythromycin, 38:189
Human monocytic cell line Mono Mac 6, nonsteroidal anti-inflammatory drugs (NSAIDs), 37:179
hu-PBL-*scid*, immunotoxicity assessment, 37:83
Hydralazine, effects, 38:157

6β-Hydroxycortisol, Enzyme-linked immunosorbent assay (ELISA), 38:71
Hypersensitivity
antigen localization, 37:15
delayed-type and immediate-type, 37:91
Hypothermia, alfentanil, 38:99

I
ICAM antibody, renal ischemia-reperfusion injury, 37:1
IgG, *hu*-PBL-*scid* mouse model, 37:83
IgM, *hu*-PBL-*scid* mouse model, 37:83
Image analysis, Feulgen-stained nuclei, 37:105
Immunoblotting, flavin-containing monooxygenase (FMO3), 37:61
Immunosuppressive drugs, delayed-type and immediate-type hypersensitivity reactions, 37:91
Immunotoxicity assessment, *hu*-PBL-*scid* mouse model, 37:83
In situ nick-end labeling (TUNEL), apoptosis analysis, 37:215
In vivo, dopamine release measurement, 37:143
Incubation system, rat liver slices, 38:59
Independence, agonist interactions, 37:167
Inflammation
ear edema, 38:53
TNF-α, 37:55
Interleukin-5 (IL-5), scintillation proximity assay, 37:161
Intestinal absorption, accelerated infusion, 37:47
Intracellular pH, angiotensin II, 37:205
Ischemia, renal, 37:1
Isolation, hepatocyte nuclei, 38:163
Isoprenaline, cardiac workload, 37:149

K
Ketoconazole, human hepatic CYP enzyme (CYP3A4) analysis with [*N*-methyl-^{14}C]-erythromycin, 38:189

L
Lactate oxidation, measurement, 38:11
Left ventricular end-diastolic pressure, adrenoceptor agonists, 37:149
Linoleic acid, peroxidation, 37:135
Lipoperoxidation, unilamellar liposomes, 37:135
Liver perfusion, in situ, 37:23
Locomotor activity
blood sampling device, 37:9
tobacco smoke effects, 38:195
Losartan, effects, 38:157
Lung mechanics, isolated perfused lung system, 38:41
Lung perfusion, isolated, 38:41
Lymphocytes, flow cytometry, 37:37

M
Mechanism of action, antineoplastic agents, 37:105
Metabolism, accelerated infusion, 37:47
Metal ions, IIb group, 38:181
Metallothionein, effects on intracellular zinc^{2+}, 38:181
Method
edema, 37:119
isolation of hepatocyte nuclei, 38:163
Metoprolol, electron-capture gas chromatographic analysis, 38:27
Micturition, rats, 38:47
Mimic, quantitative competitive polymerase chain reaction (PCR), 38:133
Mitogenicity, *hu*-PBL-*scid* mouse model, 37:83
Model, ear edema, 38:53
Modeling
agonist affinity, 38:81
cocaine pharmacokinetic/pharmacodynamic, 37:9
Monoclonal antibody, 6β-hydroxycortisol, 38:71
Monophasic action potentials (MAPs), myocardial ischemia model, 37:27
Morphonuclear effects, antineoplastic agents, 37:105
Mucosa, antigen localization, 37:15
Multiple indicator dilution studies, placental perfusion, 38:19
Myocardial contractility, angiotensin II, 37:205
Myocardial ischemia, model, 37:27
Myofilament calcium responsiveness, angiotensin II, 37:205

N
Natriuresis, renal function in noninsulin-dependent diabetic (NIDD) rat, 37:197
Nephrectomy, renal function in noninsulin-dependent diabetic (NIDD) rat, 37:197
Nitrates, organic, 38:173
Nitric oxide
dissociated cerebellar granule cells, 38:93
electrochemical microprobe, 37:97
Nonadrenergic, noncholinergic (NANC) neurotransmitter, electrochemical microprobe, 37:93
Noninsulin-dependent diabetic (NIDD) rat, renal function, 37:197
Nonsteroidal anti-inflammatory drugs (NSAIDs), cyclooxygenase inhibition, 37:179
Noradrenaline, agonist affinity, 38:81
NS398, carbonic anhydrase isoforms, 38:169
NSAIDs. See Nonsteroidal anti-inflammatory drugs (NSAIDs)

JPM Vol. 38. No. 4
December 1997:221–225

Nuclear magnetic resonance (NMR) spectroscopy, benzoic acid 1-*O*-acylglucuronide, 37:237
Nucleo-cytoplasmic transport, isolation method, 38: 163
Nucleus, isolation of hepatocyte, 38:163

O

Occulsive vascular disease, apoptosis analysis, 37:215
Operational model of agonism, 38:81
Opioid withdrawal syndrome, clonidine effects, 38: 117
Organic nitrates, epicardial coronary arteries, 38:173
Ovalbumin-challenged guinea pigs, interleukin-5 (IL-5), 37:161
Oxazolone, ear edema, 38:53
Oxygen and pH electrodes, multiple indicator dilution studies, 38:19

P

Pacing, ventricular overpacing, 37:149
PAF. See Platelet activating factor (PAF)
Pain, respiration parameters, 38:109
Para-aminohippuric acid clearance, renal blood flow, 38:33
PBMC. See Peripheral blood mononuclear cells (PBMC)
PCR. See Polymerase chain reaction (PCR)
Pentafluorobenzoyl chloride, fluvoxamine quantification, 37:129
Peripheral blood mononuclear cells (PBMC), inflammation, 37:55
Peripheral nerve embedding, silicon cement, 37:117
Permeability, edema, 37:119
pH, intracellular, angiotensin II, 37:205
pH electrodes, multiple indicator dilution studies, 38: 19
pH-stat, carbonic anhydrase isoforms, 38:169
Pharmacokinetic models, physiologically based, 38:87
Pharmacokinetic/pharmacodynamic modeling
  alfentanil, 38:99
  cocaine, 37:9
Pharmacokinetics, accelerated infusion, 37:47
Phenoxybenzamine, agonist affinity, 38:81
Phenylephrine, cardiac workload, 37:149
Phosphatidylcholine, peroxidation, 37:135
Phosphoimager analysis, quantitative competitive polymerase chain reaction (PCR), 38:133
Placental perfusion, multiple indicator dilution studies, 38:19
Plasma, hepatocyte primary culture bioassay, 38:151
Platelet activating factor (PAF), edema, 37:119
Polymerase chain reaction (PCR), quantitative competitive, 38:133
Positive inotropic intervention, angiotensin II, 37:205
Preconvulsant activity, alfentanil, 38:99
Pressure transducers, multiple indicator dilution studies, 38:19
Principal-component analysis, Feulgen-stained nuclei, 37:105
Programmed cell death, apoptosis analysis, 37:215
Proliferative factors, hepatocyte primary culture bioassay, 38:151
Prostaglandin G_2, nonsteroidal anti-inflammatory drugs (NSAIDs), 37:179
Purging, hematologic malignancies, 37:229

Q

QT interval, corrected for heart rate, 38:201
QTc interval, QT interval corrected for heart rate, 38: 201

R

Rabbits
  conscious models, 37:149
  myocardial ischemia model, 37:27
Rats
  accelerated infusion, 37:47
  computer-controlled conditioned avoidance response, 38:211
  conscious, 38:47
  liver slices, 38:59
  lymphocytes, 37:37
  nitric oxide measurement in gastric fundus, 37:93
  noninsulin-dependent diabetic (NIDD), 37:197
  opioid withdrawal syndrome, 38:117
  pain, 38:109
  renal ischemia-reperfusion injury, 37:1
  spontaneously hypertensive (SHR), 38:157
  striatum, 37:143
  tissue water content, 38:87
  tobacco smoke effects, 38:195
  unrestrained, 38:47
  urine collection, 38:47
  Wistar/Kyoto (WKY) controls, 38:157
Reactive oxygen species, nitric oxide, 38:93
Real time data analysis, isolated perfused lung model, 38:41
Reconstituted transport, Glut4, 38:1
Redox potential, coronary artery bypass graft, 38:151
Renal blood flow, calibration, 38:33
Renal effects, urine collection in rats, 38:47
Renal ischemia, reperfusion injury, 37:1
Renal plasma flow, effective, 38:33
Respiration, pain test, 38:109
Restenosis, apoptosis analysis, 37:215
Restraint, blood pressure, 38:157

Retention, computer-controlled conditioned avoidance response, 38:211
Ritanserin, depolarization-evoked [^{3}H]- acetylcholine release, 37:187
RR interval, QT interval corrected for heart rate, 38: 201

S
Scintillation proximity assay, interleukin-5 (IL-5), 37: 161
Screening, clonidine, 38:117
Serum, hepatocyte primary culture bioassay, 38:151
Silicon cement, peripheral nerve embedding, 37:117
Solid-phase extraction, buprenorphine high-performance liquid chromatography (HPLC) analysis, 37:75
Spleen, lymphocytes, 37:37
ST segment, adrenoceptor agonists, 37:149
Standards, quantitative competitive polymerase chain reaction (PCR), 38:133
Statistical moments, placental perfusion, 38:19
Stem cell transplantation, peripheral, hematologic malignancies, 37:229
Stress, effects, 38:157
Synergy, agonist interactions, 37:167

T
Telemetry
  blood pressure, 38:157
  tobacco smoke effects, 38:195
Testosterone, high-performance liquid chromatography (HPLC), 37:67
Theoretical analysis, agonist interactions, 37:167
Thrombin, vena cava perfusion in situ, 37:23
Thymus, lymphocytes, 37:37
Tissue distribution, measurement by desiccation, 38:87
Tissue water content, measurement by desiccation, 38:87
TNF-α, inflammation, 37:55
Tobacco smoke effects, radiotelemetric assessment, 38:195
Transit-time, renal blood flow, 38:33
Trypsin, vena cava perfusion in situ, 37:23
TUNEL. See In situ nick-end labeling (TUNEL)
Two-receptor: one-transducer model, agonist interactions, 37:167

U
Ultrasound flowmetry, renal blood flow, 38:33
Unilamellar liposomes, peroxidation, 37:135
Urine, 6β-hydroxycortisol, 38:71

V
Vascular smooth muscle, apoptosis analysis, 37:215
Vasopressin, effects on intracellular zinc^{2+}, 38:181
Vena cava, perfusion in situ, 37:23
Viability, incubation system, 38:59
Video angiometry, epicardial coronary selectivity, 38: 173
Virtual instrument, conditioned avoidance response, 38:211
Vocalizations, audible and ultrasonic, 38:109

Z
Zinc^{2+}, measurement of intracellular, 38:181